INTRODUCTION {#s1}
============

Human genomic aberrations have been proved to be causal factors of many diseases. Among the most widely studied variations, gene fusions have been of great interest due to their important role in human cancer. It has been estimated that 20% of human cancer are caused by gene fusions \[[@R1]\]. There are strong evidence showing that gene fusions drive the initial step and the development of cancer, and thus are potential prognostic tools or therapeutic targets in anti-cancer treatment. A convincing example is fusion gene BCR-ABL, which can be translated to an abnormal fusion protein-tyrosine kinase and drive the development of chronic myelogenous leukemia (CML). And the drug Glivec which target BCR- ABL chimeric protein has been has been proved very successful in the treatment of CML \[[@R2], [@R3]\]. Nowadays, several fundamental databases can provide fusion events involved in cancer. To our best knowledge, the following databases TICdb \[[@R4]\], dbCrid \[[@R5]\], ChimerDB 2.0 \[[@R6]\], Mitelman \[[@R1]\], and ChiTaRS \[[@R7]\] contain fusion events of human cancers.

The advances in next-generation sequencing (NGS) technologies help to detect gene fusions. Several tools based on next-generation sequencing such as Tophat-Fusion \[[@R8]\] and deFuse \[[@R9]\] are able to effectively identify novel fusion transcripts through aligning pair-end RNA-seq reads. These methods accelerated the discovery of tens to hundreds of gene fusions in various cancers, including solid tumors and hematological disorders \[[@R10]\]. However, recent studies demonstrated that minority of the gene fusions detected by next-generation based tools are important driver fusions for cancer development and most were just nonspecific passengers \[[@R1]\]. In a word, these next-generation sequencing based methods help to detect gene fusions in cancer tissues, but they failed to identify driver gene fusions.

Thus, developing a method to identify driver gene fusions was urgent. Until now, only a few attempts have been done to do this. One well established approach named Consig to distinguish driver from passenger gene fusions was proposed by Wang et al. It nominates driver fusions by the direct association of partner genes with identified fusion concept signatures, generated through enrichment of established fusions from the Mitelman database against all concepts compiled from molecular interactions, functional annotations and pathways \[[@R11]\]. This method ignored the specificity of phenotype when deducing fusion concept signatures. In addition, it is a single gene-based approach, only accounting for the impact of a single gene fusion. Protein-protein interaction network is a valuable resource for prioritization candidate gene fusions, because genes related to a specific or similar disease phenotype tend to be located in a specific neighborhood \[[@R12]\]. A computational approach named fusion centrality toward prioritization of candidate gene fusions that study network properties have been developed by Wu et al. The authors hypothesized that the partner genes of the driver fusions were prone to present as hubs in a network \[[@R13]\]. Although providing a useful tool to identify driver gene fusions, this approach also failed to account for the specificity among different cancers when using protein-protein interaction network. This means that for different cancers, a certain gene fusion candidate would get a same score by fusion centrality. What\'s more, because it only considered the impact of direct neighbors, it only explain the local topological property of network, ignoring global features.

In this work, we proposed a phenotype specific computational method called RWCFusion based gene interaction network to identify the driver gene fusions. First, we constructed a weighted gene interaction network from protein-protein interaction (PPI) network in STRING database \[[@R14]\] and mapped the high-risk cancer gene fusions into the network. Then, we developed a novel fusion pair random walk scoring method in the global network to identify phenotype-specific driver gene fusions with high-risk fusion genes acting as seed nodes. This strategy could exploit the global topology information of the network and identify phenotype-specific driver gene fusions according to the similarity between candidate fusions and seeds in the network. We evaluated the performance of RWCFusion on 483 candidate gene fusions corresponding to 35 cancer phenotypes by leave-one-out cross-validation and it achieved a high overall AUC value of 0.925 and an average of 0.929, which was much higher than other existing methods. Furthermore, we divided the 35 cancers into haematological and solid classes. Results showed they both had a good performance, especially the haematological, which got an AUC value of 0.968. Finally, we applied RWCFusion to breast cancer data to identify driver fusion genes. There were 13 fusion pairs in the top having been proved to be high-risk for breast cancer, for example, BCAS3-BCAS4, NOTCH-NUP214, MED13-BCAS3 and CARM-SMARCA4. Additionally, 8 among the top 10 of the remaining candidate gene fusions, such as SULF2-ZNF217, MED1-ACSF2, and ACACA-STAC2, were inferred to be potential driver gene fusions of breast cancer.

RESULTS {#s2}
=======

Performance of the RWCFusion {#s2_1}
----------------------------

To evaluate and execute RWCFusion, we need a basic gene interaction network and seed gene fusions at first. The gene interaction network we constructed in this article contains 16785 genes and 1515370 edges. And the seed gene fusions contains 483 high risk gene fusions altogether, corresponding to 35 phenotypes.

To evaluate the performance of RWCFusion, we used leave-one-out cross-validation for every high-risk gene fusion and plotted ROC for each of the 35 cancers, haematological, solid cancer and overall cancers separately. The ratio of all high risk gene fusions (positive) to total virtual background fusion pairs (virtually negative) is 3.4e-06 while the ratio of all involved high risk partners to all genes in the network is 3.0 e-02. Taking this into account, we balanced the test set with 1 positive gene fusion and 99 negative gene fusion in each test case of leave-one-out cross-validation \[[@R15]\].

Using RWCFusion, we got a high overall AUC value of 0.925 (Figure [1A](#F1){ref-type="fig"}), and a better one of 0.968 for haematological cancer (Figure [1B](#F1){ref-type="fig"}). For the other class solid, the AUC value is 0.867 (Figure [1C](#F1){ref-type="fig"}). And for 35 single cancer phenotype, 28 of them, such as haematological cancer CHRONIC MYELOID, MYELODYSPLASTIC SYNDROME and solid cancer THYROID CARCINOMA, LEIOMYOMA, got an AUC value higher than or equal to 0.913 (Table [1](#T1){ref-type="table"}). The mean AUC value for 35 cancers is 0.929. As is shown, haematological cancer got a high AUC value than solid cancer. We all know that genes in blood are easier to be detected than in solid tissues, which might indicate that Tophat-Fusion would got a better accuracy with haematological cancer RNA-seq data than solid when obtaining candidate gene fusions. And this might affect the performance of RWCfusion to identify drivers in candidate gene fusions in cancers. Altogether, the AUC results showed that RWCFusion performed all well for overall cancers, haematological and solid caner classes, and single cancer.

![The performance of RWCFusion evaluated by leave-one-out cross validation\
(**A**, **B** and **C**) showed the AUC results for overall cancers, haematological and solid classes respectively based on leave-one-out cross validation. (**D**, **E** and **F**) showed the number of priviously known high-risk gene fusions identified by RWCFusion.](oncotarget-07-61054-g001){#F1}

###### AUC performance of RWCFusion and existed method fusion centrality for single 35 single, haematological, solid and overall phenotype

  OMIM ID   Disease name/class                                          AUC value           
  --------- ----------------------------------------------------------- ----------- ------- --------
  159595    MYELOPROLIFERATIVE SYNDROME, TRANSIENT                      0.997       0.970   0.027
  613024    FOLLICULAR LYMPHOMA, SUSCEPTIBILITY TO, 1; FL1              0.997       0.969   0.028
  613065    LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL                          0.949       0.873   0.076
  113970    BURKITT LYMPHOMA; BL                                        0.997       0.997   0
  114480    BREAST CANCER                                               0.784       0.700   0.084
  131440    MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA     0.997       0.975   0.022
  137800    GLIOMA SUSCEPTIBILITY 1; GLM1                               0.759       0.763   −0.004
  144700    RENAL CELL CARCINOMA, NONPAPILLARY; RCC                     0.978       0.746   0.232
  150699    LEIOMYOMA, UTERINE; UL                                      0.996       0.690   0.306
  151400    LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL                          0.995       0.992   0.003
  155601    MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2; CMM2   0.703       0.883   −0.18
  167000    OVARIAN CANCER                                              0.624       0.598   0.026
  176807    PROSTATE CANCER                                             0.914       0.794   0.12
  181030    SALIVARY GLAND ADENOMA, PLEOMORPHIC                         0.993       0.838   0.155
  188550    THYROID CARCINOMA, PAPILLARY                                0.995       0.954   0.041
  211980    LUNG CANCER                                                 0.914       0.843   0.071
  215300    CHONDROSARCOMA                                              0.964       0.781   0.183
  236000    LYMPHOMA, HODGKIN                                           0.657       0.667   −0.01
  259500    OSTEOGENIC SARCOMA                                          0.73        0.707   0.023
  268210    RHABDOMYOSARCOMA 1; RMS1                                    0.997       0.959   0.038
  268220    RHABDOMYOSARCOMA 2;RMS2                                     1           0.968   0.032
  300854    RENAL CELL CARCINOMA, Xp11-ASSOCIATED; RCCX1                1           0.731   0.269
  601626    LEUKEMIA, ACUTE MYELOID; AML                                0.98        0.903   0.077
  605027    LYMPHOMA, NON-HODGKIN, FAMILIAL                             0.999       0.923   0.076
  607685    HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES                 0.999       0.971   0.028
  607785    JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML                      0.994       0.981   0.013
  608232    LEUKEMIA, CHRONIC MYELOID; CML                              0.971       0.933   0.038
  612160    HISTIOCYTOMA, ANGIOMATOID FIBROUS                           1           0.995   0.005
  612219    EWING SARCOMA; ES                                           1           0.900   0.1
  612237    CHONDROSARCOMA, EXTRASKELETAL MYXOID                        1           0.768   0.232
  612376    ACUTE PROMYELOCYTIC LEUKEMIA; APL                           0.996       0.954   0.042
  613488    MYXOID LIPOSARCOMA                                          0.936       0.858   0.078
  614286    MYELODYSPLASTIC SYNDROME; MDS                               0.979       0.893   0.086
  254700    MYELOPROLIFERATIVE DISEASE, AUTOSOMAL RECESSIVE             0.735       0.929   −0.194
  300813    SARCOMA, SYNOVIAL                                           0.996       0.427   0.569
            Solid                                                       0.968       0.903   0.065
            Haematological                                              0.867       0.77    0.097
            Overall                                                     0.925       0.845   0.080

After plotting ROC curve for overall cancers, we selected a best cutoff according to positive likelihood ratio (PLR), that is, the ratio of true positive ratio to false positive ratio. To get the best cutoff, the maximum PLR was calculated. And the cutoff correspond to the maximum PLR is taken as the best cutoff \[[@R16]\]. When using this best cutoff (0.0002125) to the test gene fusion set of 35 cancers, we identified 269(over 50%) out of the 483 previously known high-risk cancer gene fusions Figure [1D](#F1){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"}, including 189 out of 287 for haematological Figure [1D and 1E](#F1){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"} such as HMGA2-COX6C, HMGA2-CCNB1IP1 of uterine cancer and 80 out of 196 for solid Figure [1D and 1F](#F1){ref-type="fig"}, [Supplementaray Table S1](#SD1){ref-type="supplementary-material"} such as NUP98-TOP1, NSD1-NUP98 of MDS. This indicated that RWCFusion scores could be applied to classify a certain gene fusion into risk or non-risk gene fusion of disease with appropriate cutoff.

To further explore the reliability of RWCFusion, we examined the distribution of scores in all test gene fusions in leave-one-out cross-validation, including 483 high-risk gene fusions of cancers and 47817 (483 × 99) virtual gene fusions obtained from gene interaction network. After executing leave-one-out cross-validation for all cancers, we found 81% of the 483 high-risk gene fusions ranked in the top 10% of all test gene fusions. We also analyzed the top 20% of the test set and found 425 out of the 483 high-risk gene fusions were located in the top 20%, and the ratio is 88%. What\'s more, 91% high-risk gene fusions ranked in the top 30% while 96% ranked in the top 50%. From this we could see that most high-risk cancer gene fusions would get high scores with RWCFusion and ranked top in the test set.

Investigating the robustness of RWCFusion {#s2_2}
-----------------------------------------

We investigated the robustness of RWCFusion from two aspects: removing edges in the gene interaction network; setting different value of the restart probability β. For overall cancers, we calculated the AUC value after removing 10% to 50% edges of the gene interaction network separately. The result showed that RWCFusion had strong resistance against the incompleteness of the network: the AUC value only declined 0.008 when removing 10% to 50% edges ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

To investigate the influence of restart probability *β* value, we set it to 0.1, 0.3, 0.5, 0.7 and 0.9 respectively and then calculated the AUC value for overall cancers. The result showed that the overall performance of RWCFusion were stable under the perturbation of *β* and it made no significant difference no matter what we set it to ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). And in this work, we set it to 0.7 ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}).

To sum up, RWCFusion had robustness against the resistance incompleteness of the network and the restart probability *β*.

Performance comparison of RWCFusion with existing method fusion centrality {#s2_3}
--------------------------------------------------------------------------

To compare the performance of two methods, we used leave-one-out cross-validation to the 483 high-risk gene fusions corresponding to 35 cancers and calculated the AUC value for overall, two class cancers and 35 single cancers. We found the performance of RWCFusion was better than fusion centrality in overall cancers, two cancer classes and most single cancers. The overall AUC value of RWCFusion was 0.925, higher than that of fusion centrality method: 0.845 Figure [2A](#F2){ref-type="fig"}. And the AUC of haematological cancers was 0.968 for RWCFusion, higher than 0.903 for fusion centrality Figure [2B](#F2){ref-type="fig"}. As to solid cancers, it was 0.867 for RWCFusion, higher than 0.770 for fusion centrality (Figure [2C](#F2){ref-type="fig"}). Results also showed that RWCFusion got higher AUC value than fusion centrality in 30 out of 35 cancers Table [1](#T1){ref-type="table"}, Figure [2D](#F2){ref-type="fig"}. One cancer got equal AUC value between the two methods and only four cancers got AUC value lower for RWCFusion than fusion centrality (Table [1](#T1){ref-type="table"}).

![Performance compare between RWCFusion and existing method: fusion centrality\
(**A--C**) showed the AUC compare for overall cancers, haematological and solid classes respectively. (**D**) showed the top 10 AUC gap of single cancer.](oncotarget-07-61054-g002){#F2}

RWCFusion is phenotype-specific compared to fusion centrality in distinguishing driver and passenger gene fusions because high-risk gene fusions, acting as seed nodes, of each phenotype are different. However, fusion centrality fail to be phenotype-specific, which will lead to a common candidate gene fusion of different cancers getting a same score, ignoring the difference between cancers. When using leave-one-out cross-validation to the 483 high-risk gene fusions corresponding to 35 cancers, we found 16 gene fusions were shared by two different cancers. The scores of them among shared cancers in fusion centrality were the same but varied in RWCFusion (Table [2](#T2){ref-type="table"}). This result showed that RWCFusion is phenotype-specific, namely if a candidate gene fusion is detected in several different cancers at the same time, the RWCFusion scores of it for different cancers are also different because high-risk disease gene fusions of different cancers are different. This means RWCFusion can distinguish the importance of a certain gene fusion in different cancers.

###### The comparison between RWCFusion and existed method fusion centrality when scoring a common candidate gene fusion which is fused in several different cancers simultaneously

  gene1      gene2                                    OMIMID   Disease name                                              Cen-score   Our score
  ---------- ---------------------------------------- -------- --------------------------------------------------------- ----------- -----------
  FGFR1OP    FGFR1                                    159595   MYELOPROLIFERATIVE SYNDROME, TRANSIENT                    0.028       0.0019
  601626     LEUKEMIA, ACUTE MYELOID; AML             0.028    0.00017                                                               
  FGFR1OP2   FGFR1                                    601626   LEUKEMIA, ACUTE MYELOID; AML                              0.024       0.00012
  159595     MYELOPROLIFERATIVE SYNDROME, TRANSIENT   0.024    0.00098                                                               
  NUP98      TOP1                                     601626   LEUKEMIA, ACUTE MYELOID; AML                              0.027       0.00046
  159595     MYELOPROLIFERATIVE SYNDROME, TRANSIENT   0.027    0.00028                                                               
  PAPOLA     AK7                                      114480   BREAST CANCER                                             0.0087      0.000010
  176807     PROSTATE CANCER                          0.0087   0.000019                                                              
  MYO9B      FCHO1                                    176807   PROSTATE CANCER                                           0.0042      0.000003
  114480     BREAST CANCER                            0.0042   0.000016                                                              
  PAX3       NCOA1                                    268210   RHABDOMYOSARCOMA 1; RMS1                                  0.022       0.00044
  268220     RHABDOMYOSARCOMA 2; RMS2                 0.022    0.000027                                                              
  MLL        CREBBP                                   601626   LEUKEMIA, ACUTE MYELOID; AML                              0.036       0.00027
  114480     BREAST CANCER                            0.036    0.00010                                                               
  PAX3       FOXO1                                    268210   RHABDOMYOSARCOMA 1; RMS1                                  0.031       0.00050
  268220     RHABDOMYOSARCOMA 2; RMS2                 0.031    0.00069                                                               
  BCR        ABL1                                     601626   LEUKEMIA, ACUTE MYELOID; AML                              0.040       0.00037
  608232     LEUKEMIA, CHRONIC MYELOID; CML           0.040    0.00128                                                               
  BCR        JAK2                                     131440   MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA   0.049       0.00057
  601626     LEUKEMIA, ACUTE MYELOID; AML             0.049    0.00033                                                               
  CBFB       MYH11                                    601626   LEUKEMIA, ACUTE MYELOID; AML                              0.015       0.00024
  608232     LEUKEMIA, CHRONIC MYELOID; CML           0.015    0.00025                                                               
  FIP1L1     PDGFRA                                   607685   HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES               0.021       0.00072
  601626     LEUKEMIA, ACUTE MYELOID; AML             0.021    0.00014                                                               
  CCDC6      PDGFRB                                   607785   JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML                    0.025       0.00044
  608232     LEUKEMIA, CHRONIC MYELOID; CML           0.025    0.00020                                                               
  NDE1       PDGFRB                                   608232   LEUKEMIA, CHRONIC MYELOID; CML                            0.030       0.00021
  607785     JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML   0.030    0.00042                                                               
  PAX7       FOXO1                                    268210   RHABDOMYOSARCOMA 1; RMS1                                  0.026       0.00042
  FOXO1      PAX7                                     268220   RHABDOMYOSARCOMA 2; RMS2                                  0.026       0.00064
  PDGFRB     NIN                                      607685   HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES               0.025       0.00034
  NIN        PDGFRB                                   131440   MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA   0.025       0.00075

Cen-score are scores of gene fusions by scoring method fusion centrality.

Our score are scores of gene fusions by our method RWCFusion.

Case study: identify driver gene fusions in breast cancer {#s2_4}
---------------------------------------------------------

After testing the performance of RWCfusion, we applied it to breast cancer to do case study. We used Tophat-Fusion to get candidate gene fusions from pair-end RNA-seq data of breast cancer samples. We combined the gene fusions of different breast cancer samples, discarding the fusion pairs appeared in normal sample. We totally got 52 non-redundant gene fusions from six breast cancer samples and only one gene fusion NOL8P1-NOL8, which was not in breast cancer samples, in normal sample. So we initially found 52 candidate gene fusions of breast cancer through Tophat-Fusion. As for high risk gene fusions, we got 59 of breast cancer from the total 483 high risk gene fusions.

We mapped the partner genes of the 52 gene fusions of breast cancer obtained from Tophat-Fusion into the gene interaction network. 31 of them were successfully mapped and considered as final candidate gene fusions of breast cancer. Then we used RWCFusion to score and rank these candidate gene fusions according to their global functional similarity with the high-risk breast cancer gene fusions in the weighted PPI network.

Using RWCFusion, we identified 13 previously known high-risk breast cancer gene fusions, ranking in the top 13 with high scores among the 31 mapped candidates (Table [3](#T3){ref-type="table"}). For example, the fusion BCAS3-BCAS4 (breast carcinoma amplified sequence 3/4), whose partner gene BCAS3 and BCAS4 were both widely known as overexpression sequence and fusion in breast cancer \[[@R17]\], detected in MCF-7 cell line was nominated as top one fusion driver by RWCFusion. Notably, apart from the top 13, which have been proved to be high-risk breast cancer gene fusions according to ChiTaRS, we analyzed top 10 of the remaining candidate gene fusions of breast cancer whose biological roles had not been reported according to ChiTaRS, a database of fusion events in human cancers. To explore these 10 gene fusions, we searched literatures for each of them. And we found that 8 of them have potential possibility to be driver gene fusions of breast cancer (Table [4](#T4){ref-type="table"}, Figure [3](#F3){ref-type="fig"}), the details are as following. In Table [4](#T4){ref-type="table"}, the top 4 gene fusions each contains a partner gene which is also involved in a high-risk gene fusion of breast cancer, which may suggest that these 4 gene fusion may also play an important role in the occurrence and development of breast cancer. To examine the effects of a possible function of the partner genes of these 4 gene fusion in the breast cancer, we manually searched literatures and the result showed that: 1. SULF2 may act as a breast cancer suppressor, and knock-down of SULF2 in cell lines causes tumorigenic phenotypes, including increased proliferation, enhanced survival, and increased anchorage-independent growth \[[@R18]\]. 2. MED1 plays an important role in mediating resistance to the pure anti-estrogen fulvestrant both *in vitro* and *in vivo* and knockdown of MED1 potentiated tumor growth inhibition by fulvestrant \[[@R19]\]. 3. ACACA is a target gene of BRCA1, preventing its dephosphorylation through BRCA1 protein banding to it, while BRCA1 is widely known as a breast cancer susceptibility gene \[[@R20]\]. 4. STARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling \[[@R21]\]. Taken together, these top four gene fusions, containing one partner gene involved in the high-risk gene fusions of breast, have a partner gene playing as a suppressor or elevated role in the occurrence and development of breast cancer.

###### The previously known high-risk gene fusions of breast cancer identified by RWCFusion

  left gene   right gene   score
  ----------- ------------ ----------
  BCAS3       BCAS4        0.006677
  NOTCH1      NUP214       0.006672
  MED13       BCAS3        0.006652
  CARM1       SMARCA4      0.006652
  RPS6KB1     SNF8         0.006636
  VMP1        RPS6KB1      0.006635
  ARFGEF2     SULF2        0.006611
  GLB1        CMTM7        0.006606
  MED1        STXBP4       0.006604
  VAPB        IKZF3        0.006588
  PKIA        RARA         0.006582
  MYO9B       RAB22A       0.006577
  CYTH1       EIF3H        0.006574

###### The top 10 of remaining gene fusions of breast cancer ranked by RWCFusion apart from the previously known high-risk gene fusions in Table [3](#T3){ref-type="table"}

  left gene                                   left chr          left coordinates   right gene   right chr   right coordinates   RWCFusion score
  ------------------------------------------- ----------------- ------------------ ------------ ----------- ------------------- -----------------
  SULF2[\*](#tfn_001){ref-type="table-fn"}    20q13.12-q13.13   46415148           ZNF217       02q13       52210294            0.000333
  52210645                                                                                                                      
  MED1[\*](#tfn_001){ref-type="table-fn"}     17q12             37595417           ACSF2        17q21       48548388            0.00332
  ACACA[\*](#tfn_001){ref-type="table-fn"}    17q12             35479452           STAC2        17q12       37374425            0.00329
  STARD3[\*](#tfn_001){ref-type="table-fn"}   17q12             37793483           DOK5         20q13       53259996            0.00329
  USP32[\#](#tfn_002){ref-type="table-fn"}    17q23             58342772           PPM1D        17q23       58679978            0.0000642
                                                                                                            46371087            
  THRA[\#](#tfn_002){ref-type="table-fn"}     17q21             38243105           SKAP1        17q21       46371708            0.0000567
                                                                                                            46384692            
  PPP1R12A                                    12q21             80211173           SEPT10       2q13        110343414           0.0000322
  AHCTF1                                      1q44              247094879          NAAA         4q21        76846963            0.0000241
  TOB1[\#](#tfn_002){ref-type="table-fn"}     17q21             48943418           SYNRG        17q12       35880750            0.0000238
  SUMF1[\#](#tfn_002){ref-type="table-fn"}    3p26              4418013            LRRFIP2      3p22        37170639            0.0000161

Partner genes that involved in a previously known high-risk gene fusion of breast cancer according to CHiTaRs at the same time.

Partner genes that play important roles in the occurrence and development of breast cancer according to literatures evidence.

![The fusion sites of the top 2 potential driver gene fusions of breast cancer identified by RWFusion\
(**A**, **C**) showed the chromosome location the fusion happened. (**B**, **D**) showed the reads that covered the breakpoints.](oncotarget-07-61054-g003){#F3}

Apart from the top 4 gene fusions in Table [4](#T4){ref-type="table"}, the other all gene fusions in this table contain no partner genes involved in any high-risk gene fusions of breast cancer. To investigate the potential function the remaining 6 gene fusions, we manually searched literatures for each of them. The results showed that 4 of them contained a partner gene that play an important role in the occurrence and development of breast cancer. 1. USP32 was found to be overexpressed more than twofold in 9 of 18 breast cancer cell lines compared to normal breast tissue, and upregulation of USP32 in mammary epithelial cells may be important in pathogenesis of breast cancer and/or serve as a useful biomarker in breast cancer cells \[[@R22]\]. 2. Few studies have addressed the question of the impact of THRA copy number variation in breast cancer, but it is reported to be amplified with HER2 in 50 to 80% of HER2-amplified breast cancers \[[@R23]\]. 3. TOB1 is regulated by EGF-Dependent HER2 and EGFR signaling and TOB1 protein expression and phosphorylation is associated with EGF-dependent erbB signaling and proliferation in breast cancer \[[@R24]\]. 4. SUMF1 is located in aUPD regions, which is a common and non-random molecular feature of breast cancer \[[@R25]\].

As Table [4](#T4){ref-type="table"} showed that the 8 gene fusions whose partner gene is associated with breast cancer are all involved in chromosome 17q. It has been reported that loss of heterozygosity on 17q region has been found in breast cancer \[[@R26]\]. This is consistent with the fact that 8 potential driver gene fusions of breast cancer we found are all involved in chromosome 17q. Taken together, we found 13 previously known high-risk gene fusions of breast cancer such as BCAS3-BCAS4, NOTCH- NUP214, MED13- BCAS3 and CARM-SMARCA4, and 8 potential drivers such as SULF2-ZNF217, MED1-ACSF2 (Table [3](#T3){ref-type="table"}, Table [4](#T4){ref-type="table"}).

DISCUSSION {#s3}
==========

Gene fusions, one of human genomic aberrations, are believed to be causal factors of a variety of diseases. Identification of driver fusion genes associated specific cancer is still a challenge. It is believed that genes related to a specific or similar disease phenotype tend to be located in a specific neighborhood \[[@R12]\]. In this work, we proposed a network based method named RWCFusion to identify phenotype-specific cancer driver fusions. Our method assigns a score which reflects the global similarity of candidate gene fusion to known high risk fusions of a cancer to each candidate. In the beginning, the scores are 1 for seed high risk partner genes and 0 for candidate partners. They would be reassigned during the iteration in the process of RWCFusion. Two important elements determined the final score assigned to the candidate gene fusions: the weight involved distance to seed nodes and the number of seed nodes near the candidates. Scores of fusion pairs is the integrated results of their partner genes. A candidate gene fusion pair with a high score is close to the known high risk gene fusions of disease at a global scale. So it is more likely to be a driver gene fusion of tumor progression. The largest advantage of our method is that it can fully exploit interaction information of the network during the iteration at a global scale. This indicates RWCFusion can miner more information contained in the network than local network based method.

Many exploration had been made in the field of gene fusion research. For example, some previous studies often evaluated the oncogenic role of gene fusions by their recurrence, but limited success has been made \[[@R11]\]. Recent findings showed that many fusions important for development of cancer are non-recurrent, and some recurrent fusion genes founded from cancer cells also present in normal cells \[[@R27]\]. Apart from exploring the recurrence of gene fusion, there are also some other attempts have been made to characterize gene fusion. For example, fusion centrality method \[[@R13]\] similar to ours was proposed to distinguish 'driver' from 'passenger' gene fusions. We compared our method RWCFusion with fusion centrality, the results showed RWCFusion performed better than fusion centrality.

RWCFusion can be improved in the following directions. Firstly, it depends on the topology of the gene interaction network, so the low-quality and incompleteness of relation information may limit its performance. The performance could be further improved after more accurate and complete reconstructions of the network being made. Secondly, the quality and number of high-risk cancer gene fusions from the database might have influence on the performance. The continuing endeavor for accurate and quantified high-risk fusion information would further enhance our method. We hope that it will facilitate the research of mechanism of cancer development, potential prognostic and therapeutic targets in anti-cancer treatment.

MATERIALS AND METHODS {#s4}
=====================

Gene interaction network {#s4_1}
------------------------

To get gene interaction network, we first downloaded the human protein interaction data (9606.protein.links.detailed.v9.0.txt.gz) from STRING (<http://string-db.org/>) database \[[@R14]\] and converted it into gene interaction network. STRING (The Search Tool for the Retrieval of Interacting Genes, v9.0) acting as a "one-stop shop", provides integrated information of distinct types and sources of protein--protein association \[[@R14]\]. Several other resources that are currently being actively maintained are similar to STRING, such as: VisANT \[[@R28]\], GeneMANIA \[[@R29]\], N-Browse \[[@R30]\], I2D \[[@R31]\], APID \[[@R32]\] and ConsensusPathDB \[[@R33]\]. However, STRING is one of the very few sites to hold experimental, predicted and transferred interactions, together with interactions obtained through text mining. What\'s more, the links are weighted in the database, which will help to identify the most important nodes of interest in the network.

The PPI in STRING database are weighted with eight feature scores ranging from 0 to 1000, including neighborhood, fusion, co-occurence, co-expression, experimental database, text-mining and combined score which is the comprehensive score generated by STRING \[[@R14]\]. Here we choose "combined score" as the final weight, and the higher the score is, the closer the relationship of the two proteins is. After getting the weighted PPI network, we converted it into corresponding gene interaction network. Specially, two genes were linked if the proteins they encode interact with each other in STRING database. If two genes are corresponding to several different proteins respectively, the weight of this gene interaction pair is the mean value of the weights of their related protein interactions. And if two proteins are encoded by the same gene, it would be linked to itself after converting protein to gene. This kind of relationship would next be discarded in the gene interaction network. Finally the weight of edges in the network were normalized to 0--1 through dividing the weight in the protein interaction network by 1000.

Obtain high-risk gene fusions of cancers {#s4_2}
----------------------------------------

We downloaded gene fusions of cancers from ChiTaRS database (<http://chitars-old.bioinfo.cnio.es/>), which contains human cancer breakpoints. The breakpoints in ChiTaRS were extracted from the TICdb \[[@R4]\], dbCrid \[[@R5]\], ChimerDB 2.0 \[[@R6]\] and Mitelman \[[@R1]\] databases. ChiTaRS database stores totally 1892 human cancer breakpoints, which were screened out manually through inspecting more than 7000 articles \[[@R7]\]. We obtained all human cancer breakpoints and their corresponding phenotypes from ChiTaRS database Figure [4B](#F4){ref-type="fig"}. Furthermore, we use OMIM database to normalize disease names and removed duplicated fusion genes within a certain phenotype, as different breakpoints may lie in same genes. Afterwards, we discarded those fusions with one or both of its partner genes not appearing in the gene interaction network. Finally, we screened out the phenotypes that had at least two gene fusions. (See Supplemental Information)

![The flow diagram of RWCFusion\
(**A**) candidate gene fusions. (**B**) high-risk gene fusions. (**C**) and (**D**). the process of coring by RWCfusion. The nodes with rectangle shape represent partner genes of candidate gene fusions predicted by TopHat-Fusion, and the color of them reflect their scores by RWR: gray represent initial scores 0 and different level of red color reflects scores after RWR, the deeper the red color is, the higher RWR score it has. The nodes with circle shape represent partner genes of previously known high-risk gene fusions. The red color represent their initial score 1 before RWR. The straight line between two nodes (B, D) indicate that they are known or predicted to be fused.](oncotarget-07-61054-g004){#F4}

Given the fact that human cancer fusion events in ChiTaRS database were confirmed \[[@R7]\] as described before, we defined fusion pairs recorded in ChiTaRS database as "high-risk" human cancers gene fusions.

RNA-Seq data {#s4_3}
------------

We analyzed the RNA-seq data from breast cancer, which contained seven samples related to 4 breast cancer and 1 normal cell lines. And the accession number of the breast cancer pair-end RNA-seq data is SRP003186 in SRA database. The samples in the data are one normal sample and 6 breast cancer sample related to 4 cell lines, including SK-BR-3, BT-474, MCF-7 and KPL-4. There were two biological replicates for BT-474 and SK-BR-3 each, of which the length of library fragments is 100 bp and 200 bp respectively.

Obtain candidate gene fusions {#s4_4}
-----------------------------

Before identifying drivers from candidate gene fusions, the key step is actually to obtain candidate gene fusions. Tophat-Fusion is an algorithm developed to predict gene fusions by searching transcripts spanning gene fusion site and predict gene fusions by aligning pair-end RNA-seq reads without relying on existing annotation to genome \[[@R8]\]. Here we accessed Tophat-Fusion through Tophat-2.0.6, and the annotation file of the human genome is UCSC genome browser, hg19. We used TopHat-Fusion to obtain gene fusions from RNA-seq Figure [4A](#F4){ref-type="fig"}. Fusions that detected only in cancer samples compared to normal samples are defined as candidate fusions.

The RWCfusion method {#s4_5}
--------------------

We developed RWCFusion method to identify cancer driver gene fusions in different cancers from candidates according to their global functional similarity with high-risk cancer gene fusions in the gene interaction network (Figure [4A--4D](#F4){ref-type="fig"}).

A gene fusion is hybridized by two previously separate genes, the effect on disease of a fusion can be inferred by its partners \[[@R11], [@R13]\]. First, we divided the high-risk and candidate driver gene fusion pairs of disease into single genes. If one or both partner genes in the of the high-risk and candidate cancer gene fusion pairs were not in the gene interaction network, the fusion pair would be discarded later on.

Second, we mapped single genes of divided high-risk and candidate disease driver gene fusions into the gene interaction network, and took partner genes of high-risk disease gene fusions as seed nodes and then employed a random walk with restart (RWR) \[[@R34]\] to score all the nodes in the network according to their global functional similarity with the seed nodes. After scoring all nodes in the network, we extracted the partner genes of divided candidate disease gene fusions and their scores in *p*^∞^. RWR simulates as an iterative walker transiting from current node to a randomly selected neighbor starting at a given seed node s, with an additional allow the restart of the walk in each step at node s with probability *β*. Formally, the random walk with restart is defined as: $$p_{t + 1} = (1 - \beta)W^{T}p_{t} + \beta p_{0}$$ Where *W* represented the normalized adjacent matrix of the gene interaction network and *W~ij~* is the weight between gene *i* (*g~i~*) and gene *j* (*g~j~*). Here *p*~0~ is the initial probability vector and *p~t~* is a vector in which the *i-- th* element holds the probability of random walker being at node *i* at step *t*. Here, the *i--th* element in *p*~0~ is 1 if *g~i~* is seed node and 0 if it is non-seed. Parameter *β* is the restart probability ranging from 0 to 1. At each step, the random walker can return to seed nodes with probability *β*. The probability will reach a steady state *p*~∞~ by performing the iteration until the variation between *p~t+1~* and *p~t~* (measured by L1 norm) is less than 10^−10^.

Third, we integrated the scores of the left partner genes (*g~l~*) and the right partner genes (*g~r~*) of the candidate gene fusions that were divided before to get the sores of the gene fusion. The scores of the candidate gene fusions *g~l~* -- *g~r~* were defined as: $$S_{l - r} = \frac{g_{l}(p^{\infty}) + g_{r}(p^{\infty})}{2}$$

Where *S~l--r~* was the final score of the gene fusion between *g~l~* and *g~r~*. *g~l~* (*p*^∞^) is the final score of *g~l~* in RWR, whereas *g~r~* (*p*^∞^) is that of *g~r~*. Candidate gene fusions were ranked according to *S~l--r~*. The gene fusion with higher score would be more possible to be driver gene fusion of the disease.

Performance measurement {#s4_6}
-----------------------

To evaluate the performance of RWCFusion, we used leave-one-out cross-validation for every high-risk gene fusion. For every phenotype, each of the high risk gene fusion would be taken as held-out fusion in each test case. For each test case, the remaining high risk gene fusions were used as seed gene fusions. Then we generate virtual candidate fusion genes by randomly selecting gene pairs from the gene network. These randomly generated virtual fusion genes were considered as negative set of test, while the held out one was positive set of test in each test case. We calculated RWCFusion scores for every gene fusion in the test set in the each test case.

The receiver operator characteristic (ROC) curve could be plotted and the area under this curve (AUC) could be calculated according to above results. The ROC curve plots the true-positive rate (TPR) versus the false-positive rate (FPR). The held out one gene fusion in each test case was considered as positive test set, while the randomly selected fusions were considered as negative test set. Taking the RWCFusion scores of all candidates in each test case of a phenotype together, we could plot ROC curve and calculate AUC for every phenotype respectively. And by taking the RWCFusion scores of all candidates in each test case of all phenotypes together, we could calculate the overall performance of RWCFusion. As we all know, cancers are clinically classified into two classes namely haematological and solid. So we also evaluated the performance of our method for this two classes respectively in the same way.

Fusion centrality {#s4_7}
-----------------

Fusion centrality is a network analysis method to prioritize gene fusions and the author believe that a fusion is more likely to be an oncogenic driver if its two partner genes act like hubs in a network \[[@R13]\]. A new node in a network, representing the two partner genes, inherits all the linkages of its partner genes. The centrality of the new node represents the importance of a fusion in a network. Centrality of a fusion is defined as its total linkages, namely, degree. We will compare our method RWCFusion with fusion centrality in this work.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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